(Web Desk Monitoring) — Researchers at MedUni Vienna have identified a new prognostic marker, AF1Q, which could enhance personalized treatment for gastric cancer and improve patient survival rates.

This study, published in Scientific Reports, was led by Elisabeth Gruber from the Department of General Surgery and Lukas Kenner from the Department of Pathology.

The team analyzed tumor samples from 182 gastric cancer patients who underwent surgery at MedUni Vienna/University Hospital Vienna. Although AF1Q was previously linked to blood cancers like leukemia, its role in gastric cancer had been largely unexplored.

The findings suggest that AF1Q could be a valuable addition to diagnostic processes for assessing the risk of cancer recurrence. “Our results justify including AF1Q in the diagnostic process,” said Kenner. Gruber added that this new marker could help identify high-risk patients early, potentially improving treatment outcomes.